Neuro-Oncology

Brain Tumor Virtual InfoCon

Retrieved on: 
Thursday, July 15, 2021
Medical specialties, Clinical medicine, Medicine, Oncology, Neurosurgery, Brain tumor, Neuro-Oncology

WHAT:Brain Tumor InfoCon features six inspirational and information-packed Virtual Sessions, followed by the opportunity for patients and families to speak directly with prominent neurosurgeons, neuro-oncologists, neuro-radiologists as well as neuropsychologists and other experts in the field.

Key Points: 
  • WHAT:Brain Tumor InfoCon features six inspirational and information-packed Virtual Sessions, followed by the opportunity for patients and families to speak directly with prominent neurosurgeons, neuro-oncologists, neuro-radiologists as well as neuropsychologists and other experts in the field.
  • Separate sessions will focus on adult, pediatric and young adult patients, as well as caregivers.
  • Brain Tumor InfoCon is a project of the Brain Tumor Foundation, one of America's pre-eminent organizations focused on early detection, the creative use of software applications and support for brain tumor patients and their families.
  • Through the use of the most up-to-date technologies, these virtual sessions provide patients and their families with the opportunity to interact with experts in the field and learn about the newest treatments and medications in our continuing battle against brain tumors.

KIYATEC Clinical Study Data Shows Test Accurately Predicts Brain Cancer Patient Response to Standard Drug Therapy Prior to Treatment

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Medicine, Oncology, Cancer treatments, Lactams, Prodrugs, Temozolomide, Teratogens, Ovarian cancer, Neuro-Oncology, Clinical trial

The results, the interim data analysis of the companys 3D-PREDICT clinical study , were published June 16, 2021 in Neuro-Oncology Advances 1, an open access clinical journal.

Key Points: 
  • The results, the interim data analysis of the companys 3D-PREDICT clinical study , were published June 16, 2021 in Neuro-Oncology Advances 1, an open access clinical journal.
  • The 3D-PREDICT study met this goal early, at its interim data analysis, an achievement that is uncommon for innovations in oncology.
  • KIYATECs test results accurately identified the patients as future temozolomide responders or future non-responders prior to the initiation of drug treatment.
  • In newly diagnosed ovarian cancer patients, KIYATECs test prospectively and accurately predicted response to first-line chemotherapy with 89% accuracy.

Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System

Retrieved on: 
Wednesday, April 7, 2021
Oncology, Health, General Health, Clinical trials, Research, Science, Biotechnology, Branches of biology, Neurology, Ventricular system, Biology, Natural sciences, Cerebrospinal fluid, Neuro-Oncology, Assay

Amir Azadi, MD is a medical oncologist specializing in neuro-oncology and an Assistant Professor in the Department of Neurology at Barrow Neurological Institute.

Key Points: 
  • Amir Azadi, MD is a medical oncologist specializing in neuro-oncology and an Assistant Professor in the Department of Neurology at Barrow Neurological Institute.
  • Dr. Azadi received his medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran.
  • In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept is developing and commercializing its cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system.
  • The Companys CSF assay identifies molecular targets for clinical decision making and provides quantitative information for monitoring treatment response.

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma

Retrieved on: 
Tuesday, March 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Brain tumor, Cancer, Oncology, Medical specialties, Health, Neuro-Oncology, Neurology, Glioma, Glioblastoma, Blastoma, High Grade Gliomas, NT-I7, NeoImmuneTech

The investigator-initiated trial is being conducted by neuro-oncologist Jian Li Campian, M.D., Ph.D., of Washington University School of Medicine in St. Louis.

Key Points: 
  • The investigator-initiated trial is being conducted by neuro-oncologist Jian Li Campian, M.D., Ph.D., of Washington University School of Medicine in St. Louis.
  • The primary endpoint of the Phase 2 part of this study is to measure the effect of NT-I7 on absolute lymphocyte count (ALC) compared to placebo control.
  • High grade gliomas (HGGs) indicate collectively the presence of grade 3 or 4 malignant tumors, which tend to grow rapidly and spread faster than tumors of a lower grade, in brain tissue.
  • Recent data suggest that the inferior survival rate in patients with glioblastoma is associated with very low T cell counts.

VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

Retrieved on: 
Monday, March 1, 2021
Cancer, Clinical medicine, Oncology, Medicine, Angiogenesis inhibitors, Ofranergene obadenovec, Glioblastoma, Dana–Farber Cancer Institute, Neuro-Oncology

The study is sponsored by Dana-Farber Cancer Institute and is being conducted through a collaboration between VBL and seven leading neuro-oncology medical centers in the U.S.

Key Points: 
  • The study is sponsored by Dana-Farber Cancer Institute and is being conducted through a collaboration between VBL and seven leading neuro-oncology medical centers in the U.S.
  • This new study builds upon our previous successful Phase 2 trial of VB-111 in recurrent glioblastoma (rGBM) while incorporating lessons learned from the GLOBE study, said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics.
  • The Phase 2 study is enrolling patients with rGBM who are scheduled to undergo a second surgery.
  • VB-111 is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.

Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 5, 2020
Neuro-Oncology

Later this month, we will share data from our Controlled IL-12 program at the 2020 Society for Neuro-Oncology Annual Meeting.

Key Points: 
  • Later this month, we will share data from our Controlled IL-12 program at the 2020 Society for Neuro-Oncology Annual Meeting.
  • During the third quarter, Ziopharm further expanded its library of T-cell receptors (TCRs) targeting shared neoantigens in hotspots for use with the Sleeping Beauty platform.
  • Ziopharm is pleased to welcome former Gilead executive Adam Levy, Ph.D., M.B.A., as EVP, Investor Relations and Corporate Communications.
  • General and administrative expenses were $6.4 million for the third quarter of 2020, compared to$4.8 millionfor the third quarter of 2019.

American Brain Tumor Association Awards 11 Research Grants to Advance Brain Tumor Research

Retrieved on: 
Friday, October 30, 2020
Brain tumor, Medical specialties, Oncology, American Brain Tumor Association, Clinical medicine, Medicine, Neuro-Oncology, Brain Tumor Funders' Collaborative

CHICAGO, Oct. 30, 2020 /PRNewswire/ -- As the nation's first nonprofit organization committed to funding brain tumor research and providing education and information across all tumor types, the American Brain Tumor Association (ABTA) persists in its mission, announcing today the investment of $368,000 towards 11 new research grants to foster innovation in diagnosis and treatment of brain tumors in adults and children.

Key Points: 
  • CHICAGO, Oct. 30, 2020 /PRNewswire/ -- As the nation's first nonprofit organization committed to funding brain tumor research and providing education and information across all tumor types, the American Brain Tumor Association (ABTA) persists in its mission, announcing today the investment of $368,000 towards 11 new research grants to foster innovation in diagnosis and treatment of brain tumors in adults and children.
  • This investment is even more critical with the COVID-19 pandemic shifting research priorities and impacting government funding for brain tumor research.
  • Medical Student Summer Fellowshipsare $3,000 grants awarded to medical students to conduct brain tumor research projects under the guidance of neuro-oncology experts.
  • Founded in 1973, the American Brain Tumor Association provides comprehensive resources to support the complex needs of brain tumor patients and caregivers, across all ages and tumor types, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnoses, treatments and care.

Targeted Therapies for Glioblastoma Becoming Critical As Increasing Incidence of Brain Cancer Rises

Retrieved on: 
Tuesday, October 13, 2020
Brain tumor, Clinical medicine, Health, Cancer, RTT, Oncology, Glioblastoma, Glioma, Blastoma, Gliosarcoma, Neuro-Oncology

Glioblastoma is a type of brain tumor that arises from the glial or supportive brain tissue called 'glioma'.

Key Points: 
  • Glioblastoma is a type of brain tumor that arises from the glial or supportive brain tissue called 'glioma'.
  • The report added that increasing incidence of brain tumors is expected to drive growth of the global recurrent glioblastoma multiforme treatment market during the forecast period.
  • As per the National Foundation for Cancer Research, GBMis the deadliest type of brain cancer, accounting for 45% of all malignant brain tumors.
  • Furthermore, according to the article published by National Brain Tumor Society, over 10% of people with brain tumors are at high risk of developing glioblastomas.

Targeted Therapies for Glioblastoma Becoming Critical As Increasing Incidence of Brain Cancer Rises

Retrieved on: 
Tuesday, October 13, 2020
Brain tumor, Clinical medicine, Health, Cancer, RTT, Oncology, Glioblastoma, Glioma, Blastoma, Gliosarcoma, Neuro-Oncology

Glioblastoma is a type of brain tumor that arises from the glial or supportive brain tissue called 'glioma'.

Key Points: 
  • Glioblastoma is a type of brain tumor that arises from the glial or supportive brain tissue called 'glioma'.
  • The report added that increasing incidence of brain tumors is expected to drive growth of the global recurrent glioblastoma multiforme treatment market during the forecast period.
  • As per the National Foundation for Cancer Research, GBMis the deadliest type of brain cancer, accounting for 45% of all malignant brain tumors.
  • Furthermore, according to the article published by National Brain Tumor Society, over 10% of people with brain tumors are at high risk of developing glioblastomas.

CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board

Retrieved on: 
Thursday, August 27, 2020
Oncology, Neurology, Brain tumor, RTT, Neuro-Oncology

"We are excited to add Dr. Wen, a neuro-oncologist with a passion for and background in investigating cures for deadly brain cancers, such as glioblastoma, to our Science Advisory Board," commented John Climaco, CEO of CNS Pharmaceuticals.

Key Points: 
  • "We are excited to add Dr. Wen, a neuro-oncologist with a passion for and background in investigating cures for deadly brain cancers, such as glioblastoma, to our Science Advisory Board," commented John Climaco, CEO of CNS Pharmaceuticals.
  • He is currently a professor of neurology at Harvard Medical School and a director of the Center for Neuro-Oncology at Dana-Farber.
  • As previously announced, CNS Pharmaceuticals recently engaged USA-based Pharmaceutics International, Inc. (Pii) and Italian BSP Pharmaceuticals SpA (BSP) for the production of the Berubicin drug product.
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.